Drug intelligence / Profile preview

BiSiChem ALK5 inhibitor (compound 11)

Development stage: Unknown
Lead developer: BiSiChem

Overview

BiSiChem ALK5 inhibitor (compound 11): sourced facts only. name: "(11), a potential clinical candidate, was synthesized by strategic incorporation" [1] target: "a potential clinical candidate, was synthesized by strategic incorporation of deuterium at potential metabolic soft spots and identified as ALK5 inhibitors." [1] developer: "BiSiChem, 3F, Pangyo-ro, 255 beon-gil 74, Bundang-gu, Seongnam 13486, Republic of Korea" [1] stage: "(11), a potential clinical candidate, was synthesized by strategic incorporation" [1]

Targets

TGFBR1

Beyond the preview

Go deeper on BiSiChem ALK5 inhibitor (compound 11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiSiChem ALK5 inhibitor (compound 11).